JP7657223B2 - 炎症性疾患および男性避妊用ｒａｒアルファ化合物 - Google Patents

炎症性疾患および男性避妊用ｒａｒアルファ化合物 Download PDF

Info

Publication number
JP7657223B2
JP7657223B2 JP2022537288A JP2022537288A JP7657223B2 JP 7657223 B2 JP7657223 B2 JP 7657223B2 JP 2022537288 A JP2022537288 A JP 2022537288A JP 2022537288 A JP2022537288 A JP 2022537288A JP 7657223 B2 JP7657223 B2 JP 7657223B2
Authority
JP
Japan
Prior art keywords
unsubstituted
compound
alkyl
pharma
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022537288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509372A5 (https=
JP2023509372A (ja
Inventor
クマル ラへジャ，ラジ
ダミアン クロウ，ポール
タオ，ハイヤン
マクニア サッチャー，スコット
Original Assignee
オルファゲン ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルファゲン ファーマシューティカルズ，インク． filed Critical オルファゲン ファーマシューティカルズ，インク．
Publication of JP2023509372A publication Critical patent/JP2023509372A/ja
Publication of JP2023509372A5 publication Critical patent/JP2023509372A5/ja
Application granted granted Critical
Publication of JP7657223B2 publication Critical patent/JP7657223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022537288A 2019-12-19 2020-12-17 炎症性疾患および男性避妊用ｒａｒアルファ化合物 Active JP7657223B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950473P 2019-12-19 2019-12-19
US62/950,473 2019-12-19
PCT/US2020/065719 WO2021127250A1 (en) 2019-12-19 2020-12-17 Rar-alpha compounds for inflammatory disease and male contraception

Publications (3)

Publication Number Publication Date
JP2023509372A JP2023509372A (ja) 2023-03-08
JP2023509372A5 JP2023509372A5 (https=) 2023-12-25
JP7657223B2 true JP7657223B2 (ja) 2025-04-04

Family

ID=74186909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537288A Active JP7657223B2 (ja) 2019-12-19 2020-12-17 炎症性疾患および男性避妊用ｒａｒアルファ化合物

Country Status (7)

Country Link
US (1) US12492177B2 (https=)
EP (1) EP4077300A1 (https=)
JP (1) JP7657223B2 (https=)
CN (1) CN115335367B (https=)
AU (1) AU2020408043A1 (https=)
CA (1) CA3165166A1 (https=)
WO (1) WO2021127250A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492177B2 (en) 2019-12-19 2025-12-09 Orphagen Pharmaceuticals, Inc. RAR-α compounds for inflammatory disease and male contraception

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507204A (ja) 1997-06-24 2002-03-05 アラーガン・セイルズ・インコーポレイテッド ネガティブホルモン活性および／または拮抗薬活性を有するレチノイド化合物の合成と使用
US20040077710A1 (en) 2002-10-22 2004-04-22 Chandraratna Roshantha A. Methods of treatment during vascular procedures
WO2018099949A1 (de) 2016-12-01 2018-06-07 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren und vorrichtung zur georeferenzierung von luftbilddaten mit hilfe von sar-bilddaten

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6521641B1 (en) * 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
AU757448B2 (en) 1998-10-08 2003-02-20 Allergan, Inc. Male anti-fertility agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
DK3204357T3 (da) 2014-10-10 2022-04-04 High Force Res Limited Fluorescerende, syntetiske retinoider
WO2017201200A1 (en) 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
EP3709990A4 (en) * 2017-11-17 2021-12-01 The Regents of the University of California MANIPULATION OF THE RETIC ACID SIGNAL PATH
CN114041070B (zh) 2018-11-19 2024-03-08 棱镜传感器公司 边缘式光子计数检测器
US12492177B2 (en) 2019-12-19 2025-12-09 Orphagen Pharmaceuticals, Inc. RAR-α compounds for inflammatory disease and male contraception

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507204A (ja) 1997-06-24 2002-03-05 アラーガン・セイルズ・インコーポレイテッド ネガティブホルモン活性および／または拮抗薬活性を有するレチノイド化合物の合成と使用
US20040077710A1 (en) 2002-10-22 2004-04-22 Chandraratna Roshantha A. Methods of treatment during vascular procedures
WO2018099949A1 (de) 2016-12-01 2018-06-07 Deutsches Zentrum für Luft- und Raumfahrt e.V. Verfahren und vorrichtung zur georeferenzierung von luftbilddaten mit hilfe von sar-bilddaten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，1997年，40，2445-2451

Also Published As

Publication number Publication date
CN115335367B (zh) 2024-08-13
CN115335367A (zh) 2022-11-11
AU2020408043A1 (en) 2022-07-28
US20230357175A1 (en) 2023-11-09
WO2021127250A1 (en) 2021-06-24
JP2023509372A (ja) 2023-03-08
US12492177B2 (en) 2025-12-09
EP4077300A1 (en) 2022-10-26
CA3165166A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
JP7432562B2 (ja) アリール受容体モジュレーターならびにその作製および使用方法
JP6122055B2 (ja) 核内受容体結合剤
JP6337109B2 (ja) ナトリウムチャネルの調節剤としてのスルホンアミド
JP2023075282A (ja) オピオイド受容体リガンド並びにそれらの使用方法及び製造方法
CN107980042B (zh) 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
TW202014186A (zh) 作為核轉運調節劑之化合物及其用途
JP2011502148A (ja) 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
JP2022095820A (ja) ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法
JP2009543872A (ja) 選択的アンドロゲン受容体調節薬、その類似体及び誘導体とそれらの使用
JP2012507533A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
JP6942726B2 (ja) クロメン化合物および第２活性薬剤の併用薬
CN102970870A (zh) 核受体结合剂
KR20020087382A (ko) 진성 당뇨병 치료를 위한 벤조산 유도체
JP7090611B2 (ja) ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
WO2019052557A1 (zh) μ-阿片受体激动剂及其制备方法和在医药领域的应用
CN108026142A (zh) 孤儿核受体Nur77 的配体及其用途
JP7657223B2 (ja) 炎症性疾患および男性避妊用ｒａｒアルファ化合物
CA2333868A1 (en) Pharmaceutical compositions for the treatment of itching comprising pgd2 receptors antagonists
CA3217096A1 (en) Contraceptive compounds and methods
JP2020533337A (ja) 重水素原子置換インドールホルムアミド誘導体、その調製方法、およびその医療用途
AU2019274580B2 (en) Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
AU2001214046A1 (en) Treatment of sexual dysfunction using bombesin antagonist
WO2025140721A1 (zh) 腙类化合物、其药物组合物及其应用
WO2025045124A1 (zh) Soat1抑制剂及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221018

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250325

R150 Certificate of patent or registration of utility model

Ref document number: 7657223

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150